NVO Novo Nordisk Capital Markets Day: CEO Says Wegovy Pill Has Reached 7M U.S. Prescriptions as Company Expands Beyond Obesity ⠀ · CEO says the Wegovy pill has reached 7M prescriptions in the U.S. and that Novo has "gained market share quite a bit" over recent months. · Novo plans to strengthen diabetes care while further diversifying into liver disease, cardiovascular and a new Blood & Endocrine Disorders segment. · An additional 4,000 personnel exits bring total down

NVO Novo Nordisk Capital Markets Day: CEO Says Wegovy Pill Has Reached 7M U.S. Prescriptions as Company Expands Beyond Obesity ⠀ · CEO says the Wegovy pill has reached 7M prescriptions in the U.S. and that Novo has "gained market share quite a bit" over recent months. · Novo plans to strengthen diabetes care while further diversifying into liver disease, cardiovascular and a new Blood & Endocrine Disorders segment. · An additional 4,000 personnel exits bring total downsizing tied to the operational unification to 13,000 employees.